The Board of Directors is comprised of experienced professionals from the pharmaceutical and investment community, with outstanding track records.
Hamish Cameron (Chairman)
Hamish is an Operating Partner at SV Life Sciences Advisers, LLC (SVLS) and has acted as Interim CEO at X2-Pharma, Delenex Therapeutics and TopiVert Pharma and Chief Commercial Officer at ESBATech. He currently serves as a Director at Affinium, Delenex and VHsquared, in addition to TopiVert.
Before joining SVLS, Hamish was CEO of Cambridge Antibody Technology (CAT). He has also held a number of senior R&D positions at AstraZeneca/Zeneca including Head of the Cardiovascular Therapy Area, Senior Vice-President Medical Research and he was a member of the R&D Leadership Team. Hamish started his industry career with Janssen, after working in clinical practice and research in the UK. He trained as a physician and holds MBBS and BSc (Hons) Pharmacology degrees from the University of London. He is a member of the UK Royal College of Physicians and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine
Kate Bingham (Observer)
Kate is a Managing Partner at SV Life Sciences Advisers, LLC (SVLS). She has been responsible for many successful venture capital investments in biotechnology companies, since joining the firm in 1991. Kate currently serves as a Director of Autifony Therapeutics, Bicycle Therapeutics, Calchan and Convergence Pharmaceuticals. Previously, she worked in business development at Vertex Pharmaceuticals and at Monitor Company. She graduated from Harvard Business School with an MBA, where she was a Baker Scholar, and also holds a first class Masters degree in Biochemistry from the University Oxford.
Maina is Director of Healthcare Investments at Imperial Innovations. She has led a number of investments in Imperial Innovations’ healthcare portfolio since joining the company in 2006, including recent investments into Psioxus Therapeutics and Cellmedica. Maina currently serves on the board of Autifony Therapeutics, Cell Medica, Ixico and Psioxus Therapeutics as well as TopiVert Pharma. She previously worked in the research and development team at Celltech (previously Oxford Glyco Sciences), at Chimeric Therapies, a cell therapy start-up based in Philadelphia and at GeneMedicine, a gene therapy company based in Houston. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.
Dina is a Partner with NeoMed Management, having joined the firm in 2009. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001, having previously worked at 3i in London and Index Ventures in Geneva. Her recent investments include Oxular, Wilson Therapeutics, Endosense, EUSA Pharma and Novexel. She is a director on the board of Oxular and Wilson Therapeutics and has previously served on the Boards of Endosense and Microsulis.
Dina is a CFA charterholder and holds a PhD degree in Molecular and Cellular Biology from Paris VI University, France. She carried out postdoctoral research at Brown University, US and at the Fox Chase Cancer Centre, US.
Steve Webber (Chief Scientific Officer)
Steve joined TopiVert in 2011 as Chief Scientific Officer with additional responsibility for managing day to day company operations as well as leading the development of the company’s technology and pipeline.
Steve has 18 years of experience working in all phases of drug discovery, from target identification through to Phase I clinical trials. He moved to TopiVert from his previous role as Senior Director of Drug Discovery at Almirall Pharma in Barcelona. Steve also held positions of increasing responsibility in Rhone-Poulenc Rorer and Aventis and was Vice President of Biology in the Respiratory CEDD in GlaxoSmithKline.
Steve trained as a pharmacologist, with degrees from Portsmouth Polytechnic (BSc) and University College London (PhD), and is an author on over 100 peer-reviewed publications.
John Bradshaw (Chief Financial Officer)
John is a Chartered Accountant with more than fifteen years’ experience as a CFO with venture capital backed and listed companies. Following 11 years with Arthur Andersen in Cambridge and Turin, he joined Gyrus Group PLC as CFO prior to listing it on the London Stock Exchange. More recently, he has acted as the Interim CFO at Plastic Logic, a leader in plastic electronics manufacturing, and provides CFO Services to a range of companies including Heptares Therapeutics Limited, Glysure Limited and Eight19 Limited.
John has a degree in Law from the University of Liverpool.